FDA Approves First Drug for Rare Inherited Anemia

Mitapivat (Pyrukynd) is the first disease-modifying agent for hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Related Keywords

Boston ,Massachusetts ,United States , ,Agios Inc ,European Union ,Drug Administration ,Rachael Grace ,Boston Children ,Anemia ,Hematology ,Hemolytic Anemia ,Blood Transfusion ,Dyspnea ,Fatigue ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Transfusion ,Biliary Disease ,Allbladder Disease ,Gallstone ,Cholelithiasis ,Hemolysis ,